Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #71 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Advanced Enzyme Technologies Limited (this stock) | 3,050 | 38.0 | 10.3% | -15.9% | — | 66 | 41 | 11 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 190 | 54 | 39 | ₹ |
| March 31, 2026 | 203 | 60 | 45 | ₹ |
| Dec. 31, 2025 | 172 | 58 | 43 | ₹ |
| Sept. 30, 2025 | 185 | 60 | 45 | ₹ |
| June 30, 2025 | 186 | 55 | 40 | ₹ |
| March 31, 2025 | 167 | 43 | 27 | ₹ |
| Dec. 31, 2024 | 169 | 53 | 39 | ₹ |
| Sept. 30, 2024 | 146 | 42 | 33 | ₹ |
| June 30, 2024 | 155 | 49 | 35 | ₹ |
| March 31, 2024 | 158 | 40 | 30 | ₹ |
| Dec. 31, 2023 | 161 | 59 | 43 | ₹ |
| Sept. 30, 2023 | 158 | 48 | 35 | ₹ |
| June 30, 2023 | 147 | 41 | 29 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 746 | 233 | 174 |
| March 31, 2025 | 637 | 187 | 134 |
| March 31, 2024 | 624 | 188 | 137 |
| March 31, 2023 | 541 | 140 | 104 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 157 | -74 | -70 | 52 | 105 |
| March 31, 2025 | 142 | -89 | -73 | 34 | 109 |
| March 31, 2024 | 141 | -65 | -59 | 42 | 99 |
| March 31, 2023 | 140 | -298 | -26 | 38 | 102 |
| March 31, 2022 | 124 | -26 | -27 | 28 | 95 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 1,839 | 1,683 | 1,610 | 13 | 8 | 1,044 | 107 | 109 | 276 | 177 |
| March 31, 2025 | 1,621 | 1,469 | 1,398 | 12 | 9 | 880 | 97 | 94 | 293 | 157 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
